ISN Journal editorial selections on lanreotide, predicting high-risk CKD, and mitochondrial diseases
Kidney International® A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease Somatostatin analogues can reduce cyst volume in autosomal dominant polycystic kidney disease (ADPKD), but their effect on kidney function remains uncertain. This three-year randomized, placebo-controlled trial tested whether lanreotide could slow kidney function decline in adults with stage 2/3...
